Trichophyton indotineae
Jump to navigation
Jump to search
Epidemiology
Clinical manifestations
- extensive & recalcitrant infections
* image[2]
Management
- often resistant to standard terbinafine therapy
- itraconazole therapy, prolonged treatment durations may be required[2]
More general terms
References
- ↑ 1.0 1.1 1.2 Caplan AS, Todd GC, Zhu Y et al Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae. JAMA Dermatol. Published online May 15, 2024 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38748419 PMCID: PMC11097098 Free PMC article. https://jamanetwork.com/journals/jamadermatology/fullarticle/2818522
Bui TS, Katz KA. Resistant Trichophyton indotineae Dermatophytosis-An Emerging Pandemic, Now in the US. JAMA Dermatol. 2024 May 15. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38748418 https://jamanetwork.com/journals/jamadermatology/article-abstract/2818524 - ↑ 2.0 2.1 2.2 2.3 Soucheray S Drug-resistant Trichophyton fungus represents emerging threat in US. CIDRAP. May 17, 2024 https://www.cidrap.umn.edu/antimicrobial-stewardship/drug-resistant-trichophyton-fungus-represents-emerging-threat-us